Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (51-60 of 383) with videos related to

Pageof 39
Sort By:
Environmental Toxicology and Chemistry|May 6, 2003
Dehydrochlorination of 1,1,1-trichloroethane and pentachloroethane by microbially reduced ferruginous smectiteJaviera Cervini-Silva, Joel E Kostka, Richard A Larson, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2002
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemiaZhijian Qian, Anthony A Fernald, Lucy A Godley, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2012
Current practices in the management of chronic myeloid leukemiaHagop M Kantarjian, Richard A Larson, Jorge E Cortés, et al.
Genes, Chromosomes & Cancer|March 29, 2002
Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshopMette K Andersen, Richard A Larson, Nils Mauritzson, et al.
Seminars in Oncology|March 23, 2011
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?Olatoyosi Odenike, Michael J Thirman, Andrew S Artz, et al.
Haematologica|August 4, 2009
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trialFrançois Guilhot, Brian Druker, Richard A Larson, et al.
Leukemia Research|April 8, 2004
Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantationPartow Kebriaei, Jane N Winter, Ginna G Laport, et al.
International Journal of Oncology|April 6, 2006
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samplesWendy Stock, Daohai Yu, Ted Karrison, et al.
Blood|June 12, 2010
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigmRoland B Walter, Frederick R Appelbaum, Martin S Tallman, et al.
Journal of Geriatric Oncology|April 11, 2020
Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task forceHeidi D Klepin, Nina Rosa Neuendorff, Richard A Larson, et al.
Pageof 39

Showing results (51-60 of 383) with videos related to

Sort By:
Pageof 39
Environmental Toxicology and Chemistry|May 6, 2003
Dehydrochlorination of 1,1,1-trichloroethane and pentachloroethane by microbially reduced ferruginous smectiteJaviera Cervini-Silva, Joel E Kostka, Richard A Larson, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2002
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemiaZhijian Qian, Anthony A Fernald, Lucy A Godley, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2012
Current practices in the management of chronic myeloid leukemiaHagop M Kantarjian, Richard A Larson, Jorge E Cortés, et al.
Genes, Chromosomes & Cancer|March 29, 2002
Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshopMette K Andersen, Richard A Larson, Nils Mauritzson, et al.
Seminars in Oncology|March 23, 2011
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?Olatoyosi Odenike, Michael J Thirman, Andrew S Artz, et al.
Haematologica|August 4, 2009
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trialFrançois Guilhot, Brian Druker, Richard A Larson, et al.
Leukemia Research|April 8, 2004
Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantationPartow Kebriaei, Jane N Winter, Ginna G Laport, et al.
International Journal of Oncology|April 6, 2006
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samplesWendy Stock, Daohai Yu, Ted Karrison, et al.
Blood|June 12, 2010
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigmRoland B Walter, Frederick R Appelbaum, Martin S Tallman, et al.
Journal of Geriatric Oncology|April 11, 2020
Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task forceHeidi D Klepin, Nina Rosa Neuendorff, Richard A Larson, et al.
Pageof 39